Vimian Group AB (publ) (VIMGF)
OTCMKTS · Delayed Price · Currency is USD
3.620
0.00 (0.00%)
At close: Nov 21, 2024

Vimian Group AB Company Description

Vimian Group AB (publ) engages in the animal health business worldwide.

It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.

It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name.

Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.

Vimian Group AB (publ)
Country Sweden
Founded 2020
Industry Diagnostics & Research
Sector Healthcare
Employees 1,100
CEO Patrik Eriksson

Contact Details

Address:
Riddargatan 19
Stockholm, 11457
Sweden
Website vimian.com

Stock Details

Ticker Symbol VIMGF
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency EUR
ISIN Number SE0015961982
SIC Code 3841

Key Executives

Name Position
Alireza Tajbakhsh Head and Chief Executive Officer of VetFamily
Guy C. Sporri Chief Executive Officer of Movora
Stefano Santarelli Chief Executive Officer of Indical Bioscience
Magnus Kjellberg Chief Executive Officer of Nextmune
Patrik Eriksson Chief Executive Officer
Carl-Johan Zetterberg Boudrie Chief Financial Officer
Maria Dahllof Tullberg Head of IR, Communications and Sustainability
Carl-Johan Ehn General Counsel
Bart Bremer Chief People Officer
Martin Bengtson Head of M&A